High-dose IL-2 (HDIL-2) is associated with complete and durable responses in only 5-10% of patients with stage intravenous melanoma and the toxicity profile is significant. In-vivo human models have recently shown a stimulatory effect of exogenous IL-2 on both the Th17 and regulatory T-cell (T REG ) compartments. We investigated and compared the effect of HDIL-2 on the Th17 and T REG compartments in HDIL-2 responders versus nonresponders. HDIL-2 was administered at a dose of 720 000 IU/kg to patients with melanoma (n = 6) and peripheral blood was collected at baseline and at 24, 48, 72, and 96 h during treatment. Peripheral blood mononuclear cells were isolated and subjected to intracellular cytokine and extracellular receptor staining for flow cytometry. Five of six patients progressed clinically on HDIL-2 therapy, and these patients showed an increase in the frequency of T REGs on day 4 of treatment. A single patient responded to HDIL-2 therapy and showed a decrease in the frequency of T REG cells on day 4 of treatment. We found that HDIL-2 resulted in a larger increase in the frequency and total numbers of IFNγ + Th17 cells in the complete responder compared with all nonresponders. As such, the complete responder showed a high IFNγ + Th17 : T REG ratio. Our results suggest that a distinct immunophenotype may be associated with response to HDIL-2. The peripheral IFNγ + Th17 : T REG ratio may serve as an early biomarker in the setting of HDIL-2 to help identify those patients who would benefit from subsequent cycles. Melanoma Res 26:535-539 Copyright
Introduction
High-dose IL-2 (HDIL-2) is the longest used immunotherapy for advanced-stage melanoma. Although associated with significant toxicity, HDIL-2 induces complete and durable responses in 5-10% of patientsa feature unique to HDIL-2 [1] . Unfortunately, the mechanisms of HDIL-2 success and failure are poorly understood, and there is a paucity of data detailing the immunophenotypic and functional changes occurring during this treatment regimen. As such, reliable biomarkers predictive of response are lacking, and many patients experience medication-associated toxicities without oncologic benefit. Recent advancements in cancer immunotherapy have focused on the activation and function of CD8 + cytotoxic T-cells. However, CD4 + effector T-cells can also induce tumor cell death [2] . Although emphasis has been placed on IFNγ-secreting Th1 cells, a recently identified subset of effector CD4 + T-cells, Th17 cells, has shown potent antitumor effects in both in-vitro and in-vivo models [2] [3] [4] [5] [6] . Nevertheless, the role of Th17 cells in tumorigenesis remains controversial, with studies showing protumorigenic qualities of both endogenous and exogenously administered IL-17, particularly in the setting of immunodeficiency [7] [8] [9] . It appears that the effect of IL-17 on tumor growth is highly influenced by environmental factors and the effect of Th17 cells in an in-vivo human model of cancer warrants specific investigation. Previous studies have identified soluble IL-2 as an important regulator of Th17 and regulatory T-cell (T REG ) compartments, and we have recently shown that in-vivo IL-2 increases Th17 cells in patients with advanced-stage melanoma [10] . Here, we further examined the impact of HDIL-2 on the balance between Th17 and T REGs in HDIL-2 nonresponders (NRs) versus a patient showing a complete oncologic response.
Methods

Patient enrollment and sample collection
All patients undergoing HDIL-2 therapy at Emory University Hospital were enrolled in an Institutional Review Board approved protocol (IRB 46593) after informed consent was obtained (n = 6). Of the six patients treated, one patient showed a complete radiographic response to therapy, ongoing stable for 14 months (Table 1) . HDIL-2 (aldesleukin; Promethus, San Diego, California, USA) was administered as an intravenous infusion over 15 min at a dose of 720 000 IU/kg every 8 h and continued for a maximum of 5 days. Peripheral blood was collected in BD vacutainer tubes (VWR International, Radnor, Pennsylvania, USA) containing 0.1 mol/l sodium heparin. Samples were obtained before treatment and every 24 h for the duration of therapy. Peripheral blood mononuclear cells (PBMCs) were purified by density gradient centrifugation (cell preparation tubes; BD Pharmingen, San Jose, California, USA) within 12 h of sample collection and cryopreserved at − 80°C for future analysis by flow cytometry. All experiments were completed within 30 days of PBMC purification.
Ex-vivo frequency and phenotype analysis of isolated PBMCs
Extracellular staining was performed on PBMCs using the following fluorophore-labeled antibodies: CD3-Alexa700 (Biolegend, San Diego, California, USA), CD14/CD20-Pac Orange (Invitrogen, Carlsbad, California, USA), CD8-APC-Cy7 (BD Pharmingen), CD4-Pac Blue (Biolegend), CD45RA-Qdot655 (Invitrogen), and CCR7-PECy7 (Bio legend). For FoxP3 staining, cells were stained using the FoxP3 staining kit (eBioscience, San Diego, California, USA) according to the manufacturer's protocol. Frequencies of cell populations and cosignaling molecule expression were determined by flow cytometry. The flow cytometer was calibrated daily using Cytometer Setup and Tracking (CS & T) beads (BD Pharmingen). Midrange beads were utilized and photomultiplier tube voltages were adjusted before analyzing each experiment. Data were analyzed using FlowJo software (TreeStar, San Carlos, California, USA).
Ex-vivo intracellular cytokine staining
PBMCs were suspended in RPMI 1640 medium supplemented with 10% heat-inactivated fetal bovine serum, 1% L-glutamine (200 mmol/l), 1% penicillin/streptomycin (×100), 1% hepes (1 mol/l), and 1% 2-ME (14.3 mol/l) (R10). 1 × 10 6 PBMCs were placed in a 96-well plate and stimulated 4 h at 37°C with a mixture of polymermodified asphalt (Sigma-Aldrich, St Louis, Missouri, USA) and ionomycin (Sigma-Aldrich) at a concentration of 1 μg/ml each. Brefeldin A (GolgiPlug; BD Biosciences) was added to cells after 1 h of stimulation at a concentration of 1 μg/ml. Intracellular staining was performed after fixation and permeabilization according to the manufacturer's instructions (BD Biosciences) utilizing fluorophore-labeled antibodies to IFNγ-APC, IL-2-PE, and IL-17-FITC (all Biolegend). Cytokine production was determined by flow cytometry and analyzed using FlowJo software (TreeStar). Unstimulated samples measured at the baseline timepoint were utilized as negative controls and were prepared and analyzed in the same manner listed above without the addition of polymermodified asphalt/ionomycin (average frequency of IL-17 + CD4 + T-cells = 0.07 0.02% unstimulated vs. 0.5 0.07% stimulated; average frequency of IFNγ + CD4 + T-cells = 11 9% unstimulated vs. 32 14% stimulated).
Statistics
Statistical analysis was carried out using two-tailed paired Student's t-tests and linear regression models with Prism 5.0 (GraphPad) software (Graphpad Software Inc., La Jolla, California, USA). P values less than 0.05 were considered statistically significant.
Results
IL-2-induced expansion of T REGs during HDIL-2 therapy has been implicated as a potential mechanism of treatment failure [11] . We examined changes within the T REG compartment over the course of HDIL-2 therapy in two patient populations: those who responded to treatment [complete responder (CR, n = 1)] and those who did not (NR, n = 5). Flow cytometric analyses were carried out on days 0 and 4 of therapy. Five of six patients failed HDIL-2 therapy and showed an increase in T REG frequency following treatment (4% on day 0 1% to 14 6% on day 4, P = 0.06; Fig. 1b and c) . Only the CR showed a decrease in T REG frequency (9% on day 0 to 7% on day 4; Fig. 1b and c) .
Seminal studies have reported potent yet opposing effects of IL-2 on T REGs and Th17 cells, whereby IL-2 stimulates T REG development and inhibits Th17 expansion [12] . We reported previously that in-vivo IL-2 increased Th17 cells in patients with melanoma and this was associated closely with changes in the T REG compartment [10] . As Th17 cells have been shown to induce antitumor responses [2, 3] , we hypothesized that the ratio between Th17 cells and T REGs may be associated with clinical response to HDIL-2. To investigate further, we divided the absolute number of Th17 cells by T REGs to determine the ratio of circulating Th17 : T REGs within the peripheral blood. All NRs showed a Th17 : T REG ratio of less than 10 : 100 (8 Th17 cells 1 for every 100 T REGs ). The CR showed a Th17 : T REG ratio of 27 : 100 (Fig. 1e ).
Mouse models of B16 melanoma showed that Th17-mediated tumor destruction is critically dependent on IFNγ rather than IL-17 secretion [3] . We sought to investigate IFNγ production by Th17 cells in the setting of HDIL-2 in a CR and all NRs. We found that HDIL-2 increased frequency of IFNγ-producers within the Th17 compartment on day 4 of therapy in four of five patients (Fig. 1f-h) . Absolute numbers of IFNγ + Th17 cells trended toward an increase in all patients (2.1 × 10 3 cells/ ml 1.9 × 10 3 on day 0 to 14 × 10 3 cells/ml 7 × 10 3 on day 4, P = 0.06; Fig. 1i ). The CR showed a larger fold increase in absolute numbers of IFNγ + Th17 cells compared with all NRs (235% increase in IFNγ + Th17 cells/μl CR vs. 23 13% increase in IFNγ + Th17 cells/μl NR; Fig. 1j ). Changes in the frequency of IFNγ + Th17 cells correlated inversely with changes in T REG frequency (P = 0.04, Fig. 1j ). Changes in the absolute numbers of IFNγ + Th17 cells and T REGs showed a similar relationship, but this was not significant (not shown). IFNγ + Th17 : T REG ratios were calculated as above. All NRs showed an IFNγ + Th17 : T REG ratio of less than 5 : 100 (2 Th17 cells 1 for every 100 T REGs ). The CR showed an IFNγ + Th17 : T REG ratio of 20 : 100 (Fig. 1k ).
Discussion
Although our patient cohort was small, one patient showed a complete and durable response to HDIL-2, and this was associated with a distinct immunophenotype detected early in the course of therapy. We showed that response to treatment was associated with high Th17 : T REG and IFNγ + Th17 : T REG ratios. Emerging evidence identifies CD4 + T-cells as active participants during tumor rejection. CD4 + T-cells are capable of eliminating tumors resistant to CD8-mediated rejection [2] and Th17 cells specifically show superior antitumor responses compared with Th1 cells [3] .
As the number of oncologic therapies increases, it is imperative that biomarkers to help categorize patients into specific treatment arms be identified. Early lymphocytosis, vitiligo, and metastases limited to subcutaneous or cutaneous sites have been associated with an antitumor response secondary to HDIL-2; however, these parameters fail to predict response accurately in a large proportion of patients [13] . In addition, although tissue immunohistochemistry is a validated method for characterizing patterns of protein expression, proteins identified as biomarkers predictive of response to treatment (i.e. tumor PDL-1 expression as predictive of response to PD-1 blockade) [14, 15] do not function as clear-cut inclusionary or exclusionary predictors [16] . Furthermore, these assays require tissue samples for analysis. Monitoring the ratios between T-cell compartments within the peripheral blood has the benefit of easy sample collection and makes use of simple laboratory procedures, potentially serving as a valuable adjunct to currently utilized prognostic models.
We show that a high IFNγ + Th17 : T REG ratio may serve as a biomarker in the setting of HDIL-2. As mentioned above, IFNγ-secreting Th17 cells have recently received attention for their antitumor effects [3] . IFNγ has both antitumorigenic and protumorigenic functions, and its ultimate action depends on a multitude of factors including tumor profile, microenvironment, and signal strength [17] . In-vitro studies showed that IFNγ combined with IL-2 favors CD8 + cytotoxic T-cell proliferation and promotes a proinflammatory phenotype [18, 19] . These data further support measurement of peripheral IFNγ + Th17 : T REG ratios as a meaningful biomarker in the setting of HDIL-2.
In addition to higher Th17 and IFNγ + Th17 to T REG ratios, the CR showed uniquely decreased T REG frequency. This difference between CR and NRs was not observed when absolute numbers of T REGs were calculated (not shown). Thus, we posit that change in the frequency (but not absolute number) of T REGs could be used as a biomarker to ascertain the efficacy of treatment following HDIL-2. Moreover, these results suggest that it is the ratio of circulating effector CD4 + T-cells to T REGs that is more closely associated with response to treatment.
There are caveats on the interpretation of our results. Although flow cytometry allows for rapid, multiparameter phenotypic, and functional analyses of individual cells [20] , data are interpreted by hierarchical gating analysis and the boundaries between cell populations are not always easily defined. This allows for an element of subjectivity in gating strategies and in the subsequent interpretation of results. In our study, each patient served as their own control, with an unstimulated intracellular cytokine staining performed as a negative control. Furthermore, in this study, a single individual trained to operate a flow cytometer conducted all experiments and analyzed all data, helping minimize interoperator variability.
An additional limitation is the small sample size. Although HDIL-2 is still used today, very few centers are equipped to manage this treatment regimen. Furthermore, few patients are candidates for HDIL-2, given its significant toxicity profile. Accrual of additional responders (partial vs. complete) is needed to define more specifically the threshold for a 'high' Th17 or IFNγ + Th17 to T REG ratio and potentially identify an objective cut-off value to be used as a biomarker for the cessation or continuation of treatment. Identification of those patients who are most likely to benefit from HDIL-2 may lead to its focused application in this patient population.
In summary, complete response to HDIL-2 was associated with a large increase in frequency and absolute number of IFNγ + Th17 cells and a decrease in T REG frequency. Measurement of peripheral IFNγ + Th17 : T REG ratios early in the course of treatment may identify those patients who would benefit from additional cycles of HDIL-2.
